Methotrexate Accord (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting dihydrofolate to tetrahydrofolate. This inhibition disrupts the synthesis of purine nucleotides and thymidylate, leading to reduced DNA, RNA, and protein production. The effect is most pronounced in rapidly dividing cells, such as immune cells involved in inflammation and malignant tumor cells.

The specific dose of Methotrexate Accord is determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and treatment goals. Dosage regimens vary widely across indications, and the prescriber will tailor the amount and frequency to achieve optimal therapeutic effect while minimizing risk.

Methotrexate is classified as Pregnancy Category X because it is known to cause severe fetal malformations and embryotoxicity. It is contraindicated in pregnancy and should be discontinued well before conception. Breastfeeding is also not recommended, as methotrexate can be excreted in milk and may harm the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including cold‑chain if needed), and assists with any required import documentation.

Methotrexate differs from biologic agents such as TNF‑α inhibitors by acting as a small‑molecule folate antagonist that directly interferes with DNA synthesis. While biologics target specific cytokines, methotrexate provides a broader immunosuppressive effect and is often used as first‑line therapy for rheumatoid arthritis and psoriasis. Its oral or injectable forms offer flexibility, but monitoring for toxicity is more intensive than with many biologics.

Methotrexate Accord should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging to protect it from moisture and light. Do not freeze the preparation, and ensure the container remains tightly sealed when not in use.

Methotrexate Accord is supplied as a sterile injectable solution and can be given via intra‑arterial, intramuscular, or intrathecal routes, depending on the indication and clinical protocol. Administration is performed by qualified healthcare professionals under aseptic conditions, with dosing intervals and volumes determined by the treating physician.

The most serious risks include severe hepatotoxicity, bone marrow suppression leading to pancytopenia, pulmonary toxicity such as interstitial pneumonitis, and life‑threatening infections due to immunosuppression. Patients should be monitored regularly for liver enzymes, blood counts, and respiratory symptoms, and any signs of severe toxicity require immediate medical evaluation.

Methotrexate Accord is contraindicated in pregnant women, individuals with severe hepatic impairment, uncontrolled infections, and those with known hypersensitivity to methotrexate or any component of the formulation. Caution is also advised for patients with significant renal dysfunction, as dose adjustments may be necessary.